Target intelligence / Profile preview

Tectonin beta-propeller repeat-containing protein 2 (TECPR2)

Target
TECPR2
Molecular classification
Other (tectonin beta-propeller repeat-containing family; does not fit standard receptor/enzyme families), Scaffold protein, WD repeat family
01

Overview

Tectonin beta-propeller repeat-containing protein 2 (TECPR2) is a large, multi-domain scaffold protein characterized by WD repeat domains at the N-terminus and TECPR repeats with a functional LC3-interacting region at the C-terminus[1][4][8][10]. TECPR2 is essential for autophagy, facilitating autophagosome formation, and mediating their targeting and fusion with lysosomes through interactions with ATG8 family members and tethering complexes such as BLOC1 and HOPS[1][4][8]. It coordinates secretory pathway trafficking by connecting the endoplasmic reticulum, Golgi apparatus, and vesicle export machinery, ensuring efficient maturation of autophagosomes and lysosomal degradation[1][2]. Loss-of-function mutations cause neurodegenerative syndromes, primarily spastic paraplegia type 49 (SPG49), intellectual disability, and hereditary sensory/autonomic neuropathies due to impaired autophagy and neuronal waste clearance[3][4][5][8][10]. TECPR2 is not classified as a receptor, enzyme, or canonical drug target, but is significant for understanding cellular waste management and neurodegenerative disease mechanisms.

Other names
TECPR2KIAA0329SPG49WD repeat-containing protein KIAA0329/KIAA0297tectonin beta-propeller repeat-containing protein 2 isoform 1/2
02

Biological functions

Autophagy regulation (essential for autophagosome formation, targeting, and lysosomal fusion)Intracellular trafficking (ER export, ER-to-Golgi transport, vesicle trafficking)Molecular scaffold for protein-protein interactions in membrane trafficking
03

Disease associations

Neurodegenerative disease (e.g., hereditary spastic paraplegia, SPG49)Intellectual disabilityProgressive motor neuron diseaseSensory autonomic neuropathyPotential involvement in other neurodegenerative diseases with defective autophagy (Alzheimer/Parkinson/Huntington/Amyotrophic lateral sclerosis)
04

Biomarkers

Potential for biomarker development in diseases involving secretory pathway/autophagy defects, including SPG49Increased autophagosome accumulation in TECPR2-deficient tissue

Beyond the preview

Go deeper on Tectonin beta-propeller repeat-containing protein 2 (TECPR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tectonin beta-propeller repeat-containing protein 2 (TECPR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call